Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of E968. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
| ▸ | GSR | P00390 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| E968 SCHEMBL5084452 | 1.00 | CA5A (0.50) | CA5ACA5BLMNAL3MBTL1TDP1 | |
| E968 SCHEMBL21493268 | 1.00 | CA5A (0.50) | CA5ACA5BLMNAL3MBTL1TDP1 | |
| Mannitol SCHEMBL29085543 | 0.88 | LMNA (0.61) | CA5ACA5BLMNAL3MBTL1TDP1 | |
| Mannitol SCHEMBL6690019 | 0.88 | LMNA (0.61) | CA5ACA5BLMNAL3MBTL1TDP1 | |
| Mannitol SCHEMBL1241895 | 0.88 | LMNA (0.61) | CA5ACA5BLMNAL3MBTL1TDP1 | |
| Sorbitol SCHEMBL11021828 | 0.88 | LMNA (0.61) | CA5ACA5BLMNAL3MBTL1TDP1 | |
| Sorbitol SCHEMBL9470802 | 0.88 | LMNA (0.61) | CA5ACA5BLMNAL3MBTL1TDP1 | |
| Adonitol SCHEMBL20481325 | 0.88 | LMNA (0.53) | CA5ACA5BLMNAL3MBTL1TDP1 | |
| Mannitol SCHEMBL10952803 | 0.88 | LMNA (0.61) | CA5ACA5BLMNAL3MBTL1TDP1 | |
| Mannitol SCHEMBL27402277 | 0.88 | LMNA (0.61) | CA5ACA5BLMNAL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070104653-A1 | Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant | BEYOND AIR LTD (IL) | 2007-05-10 | — | — | US | claimed |
| EP-0406190-A2 | Method for producing explosive substances | Bofors Explosives AB (SE) | 1991-01-02 | — | — | EP | claimed |
| US-12636288-B2 | Methods and compositions for treating pulmonary hypertension | UNITED THERAPEUTICS CORPORATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-10987377-B2 | Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant | Advanced Inhalation Therapies (AIT), Ltd. (IL) | 2021-04-27 | — | — | US | disclosed |
| US-20200222412-A1 | METHODS AND COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION | UNITED THERAPEUTICS CORPORATION (US) | 2020-07-16 | — | — | US | disclosed |
| US-10267603-B2 | Off-axis annular precision initiation charge | SOUTHWEST RESEARCH INSTITUTE (US) | 2019-04-23 | — | — | US | disclosed |
| US-20190033044-A1 | Off-Axis Annular Precision Initiation Charge | SOUTHWEST RESEARCH INSTITUTE | 2019-01-31 | — | — | US | disclosed |
| US-20180325908-A1 | METHODS AND COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION | UNITED THERAPEUTICS CORPORATION (US) | 2018-11-15 | — | — | US | disclosed |
| US-20180250329-A1 | USE OF INHALED GASEOUS NITRIC OXIDE AS A MUCOLYTIC AGENT OR EXPECTORANT | STREETERVILLE CAPITAL, LLC | 2018-09-06 | — | — | US | disclosed |
| WO-2018132371-A2 | METHODS AND COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION | UNITED THERAPEUTICS CORPORATION (US) | 2018-07-19 | — | — | WO | disclosed |
| US-20140141098-A1 | USE OF INHALED GASEOUS NITRIC OXIDE AS A MUCOLYTIC AGENT OR EXPECTORANT | PULMONOX TECHNOLOGIES CORPORATION (CA) | 2014-05-22 | — | — | US | disclosed |
| US-20070154570-A1 | Use of nitric oxide in the treatment and disinfection of biofilms | PULMONOX TECHNOLOGIES CORPORATION (CA) | 2007-07-05 | — | — | US | disclosed |
| WO-2007057763-A2 | NITRIC OXIDE AS AN ANTI-VIRAL AGENT, VACCINE AND VACCINE ADJUVANT | PULMONOX TECHNOLOGIES CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070116785-A1 | Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant | PULMOMOX TECHNOLOGIES (CA) | 2007-05-24 | — | — | US | disclosed |
| US-20070104653-A1 | Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant | BEYOND AIR LTD (IL) | 2007-05-10 | — | — | US | disclosed |
| US-7115325-B2 | Stable aqueous suspension liquid of finely divided diamond particles, metallic film containing diamond particles and method of producing the same | Fujimura, Tadamasa (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20060147644-A1 | Stable aqueous suspension liquid of finely divided diamond particles, metallic film containing diamond particles and method of producing the same | TADAMASA FUJIMURA (JP) | 2006-07-06 | — | — | US | disclosed |
| US-20030228249-A1 | Stable aqueous suspension liquid of finely divided diamond particles, metallic film containing diamond particles and method of producing the same | NICCA CHEMICAL CO., LTD. (JP) | 2003-12-11 | — | — | US | disclosed |
| EP-1288162-A2 | Stable aqueous suspension liquid of finely divided diamond particles metallic film containing diamond particles and method of producing the same | Fujimura, Tadamasa (JP) | 2003-03-05 | — | — | EP | disclosed |
| US-5648101-A | Drug delivery of nitric oxide | TAWASHI RASHAD (CA) | 1997-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070154570-A1 | Use of nitric oxide in the treatment and disinfection of biofilms | NOS2, NOS1, NOS3 | CA5A 1435/4885CA5B 1374/4885LMNA 3383/4885 |
| US-12636288-B2 | Methods and compositions for treating pulmonary hypertension | PDE5A, PDE9A, PDE2A | CA5A 37/4885CA5B 39/4885LMNA 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.